[The protective effect of exenatide on the renal injury in diabetic rats].
Zhongguo Ying Yong Sheng Li Xue Za Zhi · 2017
Last updated 2026-05-28In a study on diabetic rats, exenatide (a GLP-1 drug) was given for 12 weeks at doses of 3 or 6 µg/kg. Compared to untreated diabetic rats, those given exenatide had lower blood sugar, HbA1c, cholesterol, and triglycerides. Their kidney function also improved, with reduced markers of damage and better antioxidant activity in kidney tissue.
AI summary of the abstract below.
| Journal | Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2017 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.14 |
| NIH percentile | 10 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
OBJECTIVE: To investigate the protective effect of exenatide (Ex) on the renal injury in streptozotocin-induced diabetic rats.
METHODS: Sprague-Dawley rats were randomly divided into 2 groups:normal control group (NC group, =8) and model group. Model group was injected with low dose of streptozotocin (30 mg·kg) after the rats were fed with high fat and high glucose diet for 4 weeks. Seventy-two hours later, rats of blood glucose level ≥ 16.7 mmol·L were divided into diabetes mellitus group (DM, =10) and two exenatide-treated groups (Ex groups,3 or 6g·kg, =8). Ex groups subcutaneously injected with exenatide for 12 weeks, but NC group and DM group were injected with the same volume of solvent. Changes in glycolipid metabolism and renal function such as serum creatinine (Scr), urine creatinine (Ucr), blood urea nitrogen (BUN), 24 hour urine micro-albumin (24 h UMA)in the 4 groups of rats were determined and creatinine clearance rate (Ccr) were calculated. Renal oxidative stress parameters such as superoxide dismutase (SOD), malondialdehyde(MDA), glutathione per-oxidase (GSH-Px) were measured. Hematoxylin-eosin (HE) staining was used to examine pathological morphology in the renal tissues and ELISA was performed to determine the level of advanced glycation end products(AGEs), the glycosylation end product in renal tissues.
RESULTS: Compared to the DM group,glycolipid metabolic abnormalities in the exenatide-treated groups were significantly ameliorated with lower levels of blood glucose,HbAlc, cholesterol and triglyceride ( < 0.05). The renal function index was markedly improved ( < 0.05) with Ccr reduced, indicating a high glomerular filtration status. Meanwhile, exenatide treatment improved the diabetes-induced pathological changes in renal morphology, substantially increased the activities of SOD and GSH-Px, and reduced the levels of MDA and AGEs.
CONCLUSIONS: Exe-natide has the renal protective effect probably by the mechanisms of inhibition of AGEs production and reduction of oxidative stress in the renal tissues of diabetic rats.
Verbatim abstract via PubMed 29931919 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.